Market Overview

Impax Labs Enters Commercialization Deal with Perrigo

Related PRGO
#PreMarket Primer: Wednesday, September 10: Dollar General Gets Aggressive
Benzinga's Top #PreMarket Losers
Horizon Inks $660M Reverse Merger With Ireland's Vidara (Fox Business)
Related IPXL
Impax Pharmaceuticals Announces Extension of RYTARY FDA Review Date To January 9, 2015
Indexes Reverse Losses; Michael Kors Beats Expectations Again

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

Posted-In: News

 

Related Articles (IPXL + PRGO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters